Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Stopped Study halted prematurely prior to initiation but potentially will resume in the future.

Conditions

• Ischemic Stroke
• Post-stroke Cognitive Impairment

Interventions

• DRUG: Cromolyn
• OTHER: Placebo

Sponsor

AZTherapies, Inc.